Comparison Of NeuroNaute Smart System to a Standard EleCTroencephalogram System in Hospital

NCT ID: NCT03379272

Last Updated: 2021-11-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2020-12-20

Study Completion Date

2020-12-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The proposed study is designed to evaluate the performance of the Neuronaute in comparison with the gold standard EEG in patients with a regular appointment at the hospital. The design of this study is guided by two overriding factors : (i) epileptics disorders suspected or either (ii) epileptics already diagnosed.

Volunteers will be asked to participate to this study. This study will enroll 35 outpatient subjects aged 18 to 85. Informed consent will be obtained from the patients, and assent from the subjects, prior to any form of assessment or intervention as part of the study.

Patients will be submitted to the studied device record Neuronaute following by the gold standard EEG.

A grid with all EEG activity recorded during the trial will be provided for evaluation after completion of the trial.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Epilepsy

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Electroencephalography Epilepsy EEG

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

GOLD STANDARD

RECORDING WITH EEG GOLD STANDARD

Group Type ACTIVE_COMPARATOR

GOLDSTANDARD

Intervention Type DEVICE

RECORDING WITH EEG GOLDSTANDARD

NEURONAUTE

RECORDING WITH THE NEURONAUTE

Group Type EXPERIMENTAL

NEURONAUTE

Intervention Type DEVICE

RECORDING WITH NEURONAUTE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GOLDSTANDARD

RECORDING WITH EEG GOLDSTANDARD

Intervention Type DEVICE

NEURONAUTE

RECORDING WITH NEURONAUTE

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients, with a regular appointment to perform an EEG recording: (i) suspected of epileptic disorders or (ii) epilepsy already diagnosed.
* Age (\> 18 years),
* Affiliated to the social security
* Informed consent.

Exclusion Criteria

* No informed consent
* Age (\< 18 years)
* No affiliation to the social security
* Unsuitable anthropometric parameters
* Pregnant women
* Recent brain surgery
* Wound or scores on the body and the scalp
* Ongoing participation in another clinical trial
* Allergy to any component from MD including : Silver, polyamide, silicone
* Sensory disorders making the patient insensitive to pain on the skin
* Behavioral disorders making the patient excessively agitated or aggressive;
* Motor or mental disorders preventing the patient from expressing his or her pain;
* Cardiorespiratory disorders likely to be aggravated by slight compression of the chest;
* The susceptibility to tension headaches (the compression exerted by the bonnet may in certain cases trigger a headache)
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pitié-Salpêtrière Hospital

OTHER

Sponsor Role collaborator

BioSerenity

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

n°2016-A01754-47

Identifier Type: -

Identifier Source: org_study_id